EIT Pharma Showcases Innovative Lonafarnib Research at 2026 Delta Cure International Meeting
EIT Pharma, Inc., a prominent biotechnology firm dedicated to developing innovative treatments for infectious diseases, made a significant impact at the 5th Edition of the Delta Cure International Meeting held in Milan, Italy. The company presented compelling new analyses concerning its investigational therapy, lonafarnib, aimed at treating Chronic Hepatitis Delta (CHD). This gathering of global experts has become one of the primary platforms for the hepatitis D community, making EIT Pharma's contributions particularly vital in advancing research and knowledge in this area.
The innovative therapy lonafarnib operates on a first-in-class mechanism designed specifically for CHD. As the New Drug Application for this treatment is under review by the U.S. Food and Drug Administration (FDA), the insights shared at this international meeting are critical for the ongoing development of this therapy. Dr. Leen Kawas, the company's Chief Executive Officer, emphasized the importance of these findings, stating, "Delta Cure has become one of the most important forums bringing together the global hepatitis D community, and we are proud to support this year's meeting and share new analyses from the lonafarnib development program."
At the conference, EIT Pharma highlighted several key presentations that shed light on the durability of response after treatment, histologic improvement, and the clinical significance of alanine aminotransferase (ALT) dynamics post-treatment. Each of these presentations provides valuable insights into how patients may respond to treatment and the health of their liver after administering lonafarnib.
One of the notable findings presented by Dr. Nancy Reau focused on histologic improvements noted during the phase 3 D-LIVR trial, which demonstrated a reduction in necroinflammation for patients undergoing therapy with lonafarnib. Additionally, Dr. Saeed Hamid shared an analysis of post-treatment responses after a comprehensive 48-week course of lonafarnib therapy, detailing a robust 24-week follow-up. Both of these presentations augmented the understanding of how lonafarnib not only aids in treating CHD but may also have lasting impacts on liver health even after treatment ceases.
Moreover, Dr. Ohad Etzion's presentation explored the clinical significance of ALT dynamics once treatment was stopped. ALT is an essential enzyme involved in liver function, and understanding its behavior post-treatment is crucial for assessing the long-term health of patients recovering from hepatitis D.
Lonafarnib represents a promising step forward in the treatment landscape for chronic hepatitis D, being the only oral therapeutic option currently undergoing late-stage clinical development. Despite it being an investigational product awaiting regulatory approval, the potential benefits outlined in the analyses discussed during the Delta Cure meeting position lonafarnib as a candidate with significant therapeutic promise.
Founded with the goal of addressing serious infectious diseases that currently lack effective treatments, EIT Pharma aims to translate scientific innovations into tangible benefits for patients facing these conditions. As part of its commitment to rigorous science and patient-centered approaches, the company continues to advance its portfolio with the hope of delivering transformative therapies.
The insights collected from the 2026 Delta Cure International Meeting underscore the evolving dialogue around hepatitis D treatment and the collaborative efforts of researchers and healthcare professionals invested in improving patient outcomes. EIT Pharma remains focused on its mission, advocating for continued research and development in the field as it strives to bring new therapies, such as lonafarnib, to market and ultimately to patients in need.
The innovative therapy lonafarnib operates on a first-in-class mechanism designed specifically for CHD. As the New Drug Application for this treatment is under review by the U.S. Food and Drug Administration (FDA), the insights shared at this international meeting are critical for the ongoing development of this therapy. Dr. Leen Kawas, the company's Chief Executive Officer, emphasized the importance of these findings, stating, "Delta Cure has become one of the most important forums bringing together the global hepatitis D community, and we are proud to support this year's meeting and share new analyses from the lonafarnib development program."
At the conference, EIT Pharma highlighted several key presentations that shed light on the durability of response after treatment, histologic improvement, and the clinical significance of alanine aminotransferase (ALT) dynamics post-treatment. Each of these presentations provides valuable insights into how patients may respond to treatment and the health of their liver after administering lonafarnib.
One of the notable findings presented by Dr. Nancy Reau focused on histologic improvements noted during the phase 3 D-LIVR trial, which demonstrated a reduction in necroinflammation for patients undergoing therapy with lonafarnib. Additionally, Dr. Saeed Hamid shared an analysis of post-treatment responses after a comprehensive 48-week course of lonafarnib therapy, detailing a robust 24-week follow-up. Both of these presentations augmented the understanding of how lonafarnib not only aids in treating CHD but may also have lasting impacts on liver health even after treatment ceases.
Moreover, Dr. Ohad Etzion's presentation explored the clinical significance of ALT dynamics once treatment was stopped. ALT is an essential enzyme involved in liver function, and understanding its behavior post-treatment is crucial for assessing the long-term health of patients recovering from hepatitis D.
Lonafarnib represents a promising step forward in the treatment landscape for chronic hepatitis D, being the only oral therapeutic option currently undergoing late-stage clinical development. Despite it being an investigational product awaiting regulatory approval, the potential benefits outlined in the analyses discussed during the Delta Cure meeting position lonafarnib as a candidate with significant therapeutic promise.
Founded with the goal of addressing serious infectious diseases that currently lack effective treatments, EIT Pharma aims to translate scientific innovations into tangible benefits for patients facing these conditions. As part of its commitment to rigorous science and patient-centered approaches, the company continues to advance its portfolio with the hope of delivering transformative therapies.
The insights collected from the 2026 Delta Cure International Meeting underscore the evolving dialogue around hepatitis D treatment and the collaborative efforts of researchers and healthcare professionals invested in improving patient outcomes. EIT Pharma remains focused on its mission, advocating for continued research and development in the field as it strives to bring new therapies, such as lonafarnib, to market and ultimately to patients in need.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.